Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in Psoriasis

Authors

  • Farah Asad
  • Moosa Khan
  • Fatima Rizvi

DOI:

https://doi.org/10.12669/pjms.336.14068

Keywords:

Atorvastatin, Betamethasone Valerate0.1%, Cardio vascular risk, Psoriasis.

Abstract

Objectives: To evaluate the effect of Atorvastatin as an adjuvant with betamethasone valerate on disease severity and cardiovascular risks in chronic plaque type psoriatic patients.

Methods: It is an interventional study conducted in Pharmacology Department of BMSI, JPMC with the collaboration of Dermatology Department of JPMC, Karachi. The duration of study was from June 2013 to June 2016.

Author Biography

Farah Asad

pharmacology ,associate professor

Downloads

Published

2017-12-20

How to Cite

Asad, F., Khan, M., & Rizvi, F. (2017). Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in Psoriasis. Pakistan Journal of Medical Sciences, 33(6). https://doi.org/10.12669/pjms.336.14068

Issue

Vol. 33 No. 6 (2017): November – December 2017

Section

Original Articles